Latest Headlines

Latest Headlines

GSK reports PhIII success for shingles jab, will file for approval in late 2016

Merck's Zostavax is the only shingles vaccine approved in the U.S. and EU, but it may not be for long. Based on results from two Phase III trials involving more than 16,000 older adults, GlaxoSmithKline plans to submit a regulatory filing for its shingles candidate, dubbed Shingrix, in North America, Japan and the EU in the second half of 2016.

Merck's Zostavax not cost-effective for those in their 50s: Study

The CDC doesn't currently recommend Merck's shingles vaccine, Zostavax, for those between the ages of 50 and 60. And a new analysis of the vaccine's cost-effectiveness in that population suggests it should stay that way.

Shingles vaccine can be beneficial even when it doesn't ward off disease

A Kaiser Permanente study shows that the shingles vaccine can reduce the long-term pain of those who contracted the disease even though they were vaccinated.

UPDATED: GSK's shingles candidate more effective than Merck's Zostavax in older adults, study says

Zostavax is the only shingles vaccine approved in the U.S. and the EU, but GlaxoSmithKline is one step closer to changing that. On Tuesday, the British pharma announced Phase III results for its shingles candidate, HZ/su, reporting an overall efficacy of 97.2% compared with placebo.

GlaxoSmithKline's shingles vaccine gets a leg up on Merck's rival with a PhIII win

GlaxoSmithKline's in-development shingles vaccine successfully staved off the virus in a massive Phase III study--and, in contrast with its top competitor, the shot's effects didn't wane among elderly patients.

Analysts: GSK shingles vaccine could steal market share from Merck's Zostavax

While GlaxoSmithKline is still awaiting late-stage results for its shingles vaccine, HZ/su, Cowen & Co. analysts believe the vaccine may just be better than Merck's Zostavax.

GSK shingles candidate hits its mark in hefty Phase III study

More than four years ago, GlaxoSmithKline began a Phase III study of a shingles candidate it hoped would eventually mount a challenge to Merck's Zostavax. Now, that candidate is one step closer after hitting its primary endpoint in that trial.

People most in need of Merck's shingles jab often not vaccinated

Not enough people are being vaccinated against shingles, and those who are at the highest risk for the painful viral infection, such as those with immunosuppressive disorders like HIV, are not able to receive the vaccine because of safety issues, according to a new study.

CDC: Adult vaccination rates are still well below targets

The National Adult Vaccination Program and others have proposed strategies to raise the proportion of adults getting vaccinated against pneumococcal disease, shingles and hepatitis B, but the latest data shows little change in immunization rates.

Quidel gains CE mark for herpes/chicken pox molecular Dx

Quidel has its latest molecular diagnostic test approval in hand, this time a CE mark for a blood test that screens for herpes plus a virus that causes chicken pox and shingles.